Search company, investor...

Founded Year

2017

Stage

Series A - II | Alive

Total Raised

$18.17M

Last Raised

$8M | 4 yrs ago

About STALICLA

STALICLA is a patient-centric biotech company on a mission to identify, develop and bring precision medicine to patients with neurodevelopmental disorders, with a first application in autism spectrum disorder.

Headquarters Location

Campus Biotech Innovation Park Avenue de Secheron 15

Geneva, 1202,

Switzerland

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

STALICLA Patents

STALICLA has filed 12 patents.

The 3 most popular patent topics include:

  • Autism
  • Psychiatric diagnosis
  • Neurological disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/18/2020

9/13/2022

Calcium channel blockers, Phosphodiesterase inhibitors, Amines, Piperidines, Xanthines

Grant

Application Date

12/18/2020

Grant Date

9/13/2022

Title

Related Topics

Calcium channel blockers, Phosphodiesterase inhibitors, Amines, Piperidines, Xanthines

Status

Grant

Latest STALICLA News

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

Jun 7, 2023

06/07/2023 | 06:42am EDT Message : *Required fields (Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July. The Cheshire, England-based clinical stage drug development company said it generated revenue of just GBP442,000 for the year ended March 31, compared to none the year prior. This came from an out-licensing deal with Stalicla for the rights to its SFX-01 asset in the treatment of neurodevelopmental disorders and schizophrenia. Evgen noted it does not have any approved or revenue generating products. However, if the out-licensing deal with Stalicla is successful, it will generate milestone payments of USD160.5 million and a double-digit royalty on sales. Evgen's annual pretax loss widened to GBP5.0 million from GBP3.2 million a year prior, as total operating expenses grew 72% to GBP5.5 million from GBP3.2 million. Chief Executive Officer Huw Jones said: "The last year has seen substantial progress in both our science and in our stated aim of out-licensing our technology in cash-generating partnerships. Of particular note is our partnership with Stalicla in autism spectrum disorder that could generate substantial non-dilutive income over a long period." On Wednesday, Evgen also said Chief Financial Officer Moulson will retire at the company's annual general meeting in late July after six years in the role. Evgen added that the search for a replacement is underway. CEO Jones commented: "I would like to express my sincere thanks to our CFO Richard, who is retiring at the AGM. His steadfast support and well considered judgements have been invaluable both to the company and to me personally." Shares in Evgen were down 4.3% at 3.78 pence each in London on Wednesday morning. By Sabrina Penty, Alliance News reporter

STALICLA Frequently Asked Questions (FAQ)

  • When was STALICLA founded?

    STALICLA was founded in 2017.

  • Where is STALICLA's headquarters?

    STALICLA's headquarters is located at Campus Biotech Innovation Park, Geneva.

  • What is STALICLA's latest funding round?

    STALICLA's latest funding round is Series A - II.

  • How much did STALICLA raise?

    STALICLA raised a total of $18.17M.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.